Hilleman Labs Advances Ebola Vaccine
Heilmann Laboratories, headquartered in Singapore, announced its intention to develop a vaccine against the Ebola virus of the Bundibugyo strain, which has caused the death of approximately 1,500 people in the Democratic Republic of the Congo. The World Health Organization indicates that this vaccine is the closest to success because it is based on the rVSV platform, the same used in the currently approved Ervebo vaccine. The new vaccine is expected to be easier to store and distribute, as it can be kept at regular temperatures, which will help accelerate its deployment to effectively combat the virus outbreak. The laboratories will expedite the development of the vaccine to begin clinical trials as part of efforts to curb the spread of Ebola in the region.
Notice: This Is an AI-Generated Summary
Comments (0)